Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 5, 2011, Pages 1322-1325

  Minelli, Alessandra ^a   Zanardini, Roberta ^a   Abate, Maria ^b   Bortolomasi, Marco ^b   Gennarelli, Massimo ^a,c   Bocchio Chiavetto, Luisella ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b Psychiatric Hospital Villa Santa Chiara   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Depression; Drug resistance; Electroconvulsive therapy; Vascular endothelial growth factor

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; THERAPY EFFECT; TREATMENT DURATION;

ADULT; AGED; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957790125     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.04.013     Document Type: Article

References (45)

1. Abrams R., Swartz C.M., Vedak C. Antidepressant effects of right versus left unilateral ECT and the lateralization theory of ECT action. Am J Psychiatry 1989, 146(9):1190-1192.
2. Altar C.A., Laeng P., Jurata L.W., Brockman J.A., Lemire A., Bullard J., et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004, 24(11):2667-2677.
3. Baghai T.C., Moller H.J. Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci 2008, 10(1):105-117.
4. Bebawy M., Chetty M. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 2008, 30(2):183-188.
5. Blumberg H.P., Wang F., Chepenik L.G., Kalmar J.H., Edmiston E., Duman R.S., et al. Influence of vascular endothelial growth factor variation on human hippocampus morphology. Biol Psychiatry 2008, 64(10):901-903.
6. Bocchio-Chiavetto L., Zanardini R., Bortolomasi M., Abate M., Segala M., Giacopuzzi M., et al. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 2006, 16(8):620-624.
7. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004, 36(8):827-835.
8. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
9. Elfving B., Plougmann P.H., Wegener G. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett 2010, 474(1):13-16.
10. Emanuele E., Orsi P., Barale F., di Nemi S.U., Bertona M., Politi P. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. Clin Biochem 2010, 43(3):317-319.
11. Fabel K., Fabel K., Tam B., Kaufer D., Baiker A., Simmons N. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 2003, 18(10):2803-2812.
12. Fulzele S., Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophr Res 2009, 115(2-3):372-373.
13. Greenberg D.A., Jin K. Experiencing VEGF. Nat Genet 2004, 36(8):792-793.
14. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34(11):2459-2468.
15. Hawkins B.T., Sykes D.B., Miller D.S. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010, 30(4):1417-1425.
16. Heine V.M., Zareno J., Maslam S., Joels M., Lucassen P.J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 2005, 21(5):1304-1314.
17. Husain N., Awasthi S., Haris M., Gupta R.K., Husain M. Vascular endothelial growth factor as a marker of disease activity in neurotuberculosis. J Infect 2008, 56(2):114-119.
18. Iga J., Ueno S., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(3):658-663.
19. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002, 99(18):11946-11950.
20. Kahl K.G., Bens S., Ziegler K., Rudolf S., Kordon A., Dibbelt L., et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34(3):353-357.
21. Kennedy S.H., Giacobbe P. Treatment resistant depression-advances in somatic therapies. Ann Clin Psychiatry 2007, 19(4):279-287.
22. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. Neuropsychopharmacology 2006, 31(1):212-220.
23. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
24. Lisanby S.H. Electroconvulsive therapy for depression. N Engl J Med 2007, 357(19):1939-1945.
25. McCloskey D.P., Croll S.D., Scharfman H.E. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J Neurosci 2005, 25(39):8889-8897.
26. Merkl A., Heuser I., Bajbouj M. Antidepressant electroconvulsive therapy: mechanism of action, recent advances and limitations. Exp Neurol 2009, 219(1):20-26.
27. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
28. Newton S.S., Collier E.F., Hunsberger J., Adams D., Terwilliger R., Selvanayagam E., et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003, 23(34):10841-10851.
29. Piccinni A., Del Debbio A., Medda P., Bianchi C., Roncaglia I., Veltri A., et al. Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009, 19(5):349-355.
30. Rush A.J., Warden D., Wisniewski S.R., Fava M., Trivedi M.H., Gaynes B.N., et al. STAR*D: revising conventional wisdom. CNS Drugs 2009, 23(8):627-647.
31. Sanacora G., Mason G.F., Rothman D.L., Hyder F., Ciarcia J.J., Ostroff R.B., et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003, 160(3):577-579.
32. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42(6):270-276.
33. Schanzer A., Wachs F.P., Wilhelm D., Acker T., Cooper-Kuhn C., Beck H., et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 2004, 14(3):237-248.
34. Segi-Nishida E., Warner-Schmidt J.L., Duman R.S. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci USA 2008, 105(32):11352-11357.
35. Senger D.R. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 2010, 21(3):377-379.
36. Shelton R.C., Osuntokun O., Heinloth A.N., Corya S.A. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24(2):131-161.
37. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26(9):943-954.
38. Tanis K.Q., Newton S.S., Duman R.S. Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord Drug Targets 2007, 6(2):151-160.
39. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(Suppl 13):23-29.
40. Tsai S.J., Hong C.J., Liou Y.J., Chen T.J., Chen M.L., Hou S.J., et al. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 2009, 169(2):113-117.
41. Uhr M., Grauer M.T., Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003, 54(8):840-846.
42. Ventriglia M., Zanardini R., Pedrini L., Placentino A., Nielsen M.G., Gennarelli M., et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(1):146-149.
43. Viikki M., Anttila S., Kampman O., Illi A., Huuhka M., Setala-Soikkeli E., et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett 2010, 477(3):105-108.
44. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007, 104(11):4647-4652.
45. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008, 8(1):14-19.